LP

Lynne Robertson, M.S., Ph.D.

Chief Scientific Officer (as Consultant) at Temple Therapeutics

Lynne Robertson, M.S., Ph.D. has extensive experience in the pharma industry and life sciences. Lynne is currently working as the Chief Scientific Officer (as a consultant) for Temple Therapeutics BV since 2018, where they are responsible for the development of Fibrosis and Oncology assets. Lynne manages contract organizations, designs clinical trials, and works with the Senior Leadership Team. Prior to this, Lynne worked as the Principal Consultant and Cofounder at Gwen Ryan Solutions, LLC since 2004. Their roles included formulating novel solutions for regulated product development and providing custom regulatory solutions. Lynne has also held executive positions as an independent contractor in various companies, including Temple Therapeutics BV and Ade Therapeutics. Lynne's areas of expertise include oncology, neurology, cardiovascular, GI, metabolic, endocrine/women's health, branded and generic drugs, biologics, OTC drugs, and regulatory compliance. Lynne has worked with multiple pharmaceutical companies, including Schering-Plough (Merck), Wyeth (Pfizer), J&J, Biogen, Mylan, and Kos Pharmaceuticals.

Lynne Robertson, M.S., Ph.D. completed their Bachelor's Degree in Biology at Providence College from 1977 to 1981. Later, they pursued a Master's Degree in Biochemistry from The Robert Larner, M.D. College of Medicine at The University of Vermont, where they studied from 1990 to 1992. Continuing their education, they earned a Ph.D. in Pharmacology from the same institution, completing their studies from 1994 to 1999.

Links

Previous companies

Merck logo
IQVIA logo

Timeline

  • Chief Scientific Officer (as Consultant)

    June, 2018 - present